Archive · 5 Dec 2025
SPL Plans R&D Unit in Hyderabad
Sai Parenterals Limited (SPL) is a company that makes medicines.
They are planning to open a new research and development center in Hyderabad, India.
They also bought a big part of another company called Noumed Pharmaceuticals in Australia.
Noumed sells medicines to stores in Australia and New Zealand.
Noumed is building a new factory in Adelaide, which will be ready by the end of 2026.
SPL thinks this will help them sell more medicines in different countries.
SPL has some investors who help them with money, like Samarsh Capital and Blue Lotus Capital.
SPL plans to set up a research and development unit in Hyderabad.
SPL acquired a 74.6% stake in Noumed Pharmaceuticals for Rs 125 crore.
Noumed is a supplier of private label OTC products in Australia and New Zealand.
Noumed is building a new manufacturing facility in Adelaide with an investment of AUD 53 million.
The new facility is expected to begin commercial operations by Q4 2026.
- Who
- Sai Parenterals Limited (SPL) and Noumed Pharmaceuticals
- What
- SPL plans to set up an R&D unit in Hyderabad and acquire a stake in Noumed Pharmaceuticals
- When
- The acquisition is already completed, and the new facility is expected to start operations by Q4 2026
- Where
- Hyderabad, India and Adelaide, Australia
- Why
- To enhance entry into semi-regulated and regulated markets with a wider, more competitive product portfolio
- Company
- Sai Parenterals Limited (SPL)
- Acquisition
- Noumed Pharmaceuticals
- Acquisition Cost
- Rs 125 crore
- Noumed Revenue
- AUD 60 million
- Noumed Facility Investment
- AUD 53 million
- Expected Completion
- Q4 2026
- Investors
- Samarsh Capital, Vyom Partners, Blue Lotus Capital, Gruhas
